Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

ELISA in Relapsed/Refractory MM — Stella

Home/Relapsed Refractory Multiple Myeloma (RRMM)/ELISA in Relapsed/Refractory MM

View on ClinicalTrials.gov

Recruiting

Back to Relapsed Refractory Multiple Myeloma (RRMM) trials

ELISA in Relapsed/Refractory MM

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

United States

Massachusetts General Hospital, Boston, Massachusetts

Beth Israel Deaconess Medical Center, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Key details

Phase

Safety & dosing

Sponsor

Massachusetts General Hospital

Collaborators

Pfizer, Sanofi

Enrollment target

~30 participants

Started

August 2025

Primary completion

December 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.